FOLH1 and Familial prostate cancer: However, a specific c-MET radioligand in PET could open the way to radioligand therapy, such as in prostate cancer with prostate specific membrane antigen (PSMA) ligand (Sartor et al. 2021) or in neuroendocrine tumours with somatostatin ligand (Strosberg et al. 2017).